| Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer CP Kung, KA Cottrell, S Ryu, ER Bramel, RD Kladney, EA Bao, ... Oncogene 40 (1), 189-202, 2021 | 46 | 2021 |
| ADAR1 editing dependency in triple-negative breast cancer CP Kung, KA Cottrell, S Ryu, ER Bramel, RD Kladney, EA Bross, ... bioRxiv, 2020.01. 31.928911, 2020 | 4 | 2020 |
| Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells KA Cottrell, S Ryu, JR Pierce, L Soto Torres, HE Bohlin, AM Schab, ... Cancer Research Communications 4 (4), 986-1003, 2024 | 3 | 2024 |
| Abstract A104: ADAR1-associated metabolic vulnerabilities in triple-negative breast cancer CP Kung, LP Shriver, N Terzich, MXG Ilagen, M Prinsen, S Ryu, ... Molecular Cancer Therapeutics 22 (12_Supplement), A104-A104, 2023 | | 2023 |
| Reducing disparities in breast cancer mortality through the identification of novel targets in triple-negative breast cancer K Cottrell, P Kung, S Ryu, L Maggi, C Kuzmicki, R Kladney, L Yiu, ... CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 32 (1), 2023 | | 2023 |
| Abstract IA012: Reducing disparities in breast cancer mortality through the identification of novel targets in triple-negative breast cancer K Cottrell, P Kung, S Ryu, L Maggi, C Kuzmicki, R Kladney, L Yiu, ... Cancer Epidemiology, Biomarkers & Prevention 32 (1_Supplement), IA012-IA012, 2023 | | 2023 |
| ADAR and DDX54 promote genomic stability in breast cancer cells S Ryu, KA Cottrell, L Soto-Torres, A Schabb, JD Weber Cancer Research 82 (12_Supplement), 842-842, 2022 | | 2022 |
| Proximity labeling reveals a role for ADAR and DDX54 in suppressing dsRNA sensing in breast cancer KA Cottrell, S Ryu, LS Torres, A Schab, JD Weber Cancer Research 82 (12_Supplement), 876-876, 2022 | | 2022 |
| Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer (vol 40, pg 189, 2021) CP Kung, KA Cottrell, S Ryu, ER Bramel, RD Kladney, EA Bao, ... ONCOGENE 40 (11), 2147-2147, 2021 | | 2021 |
| Correction to: Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer CP Kung, KA Cottrell, S Ryu, ER Bramel, RD Kladney, EA Bao, ... Oncogene 40 (11), 2147-2147, 2021 | | 2021 |
| Abstract P4-08-03: Tumor suppressors p53 and ARF control ADAR1-driven tumorigenicity in triple negative breast cancer CP Kung, CE Kuzmicki, EA Bross, S Ryu, E Freeman, T Sabloak, ... Cancer Research 80 (4_Supplement), P4-08-03-P4-08-03, 2020 | | 2020 |
